Zusammenfassung
Wir beschreiben mit dem primär renalen Angiosarkom eine seltene Tumorentität bei einem 59-jährigen Patienten. Die mittlere Überlebenszeit liegt bei wenigen Monaten, wenn die Diagnose bei klinischer Symptomatik erfolgt. Heilungschancen bestehen durch chirurgische Resektion kleinerer Zufallsbefunde. Bei fehlender Standardtherapie orientiert sich die systemische Behandlung an der Therapie anderer Weichteilsarkome. Der Stellenwert der adjuvanten Therapie bleibt unklar. Mit doxorubicinbasierten Chemotherapieregimen konnte bei Angiosarkomen ein Überlebensvorteil erreicht werden.
Abstract
This article reports a case of primary renal angiosarcoma, a very rare and aggressive malignancy, in a 59-year-old male patient. The mean overall survival time is limited to a few months if the diagnosis is made when clinical symptoms are present but chances of a cure can be increased with surgical resection of smaller incidental findings. Due to the lack of a standard therapy, systemic treatment is based on the therapy of other soft tissue sarcomas. The role of adjuvant medical treatment particularly in angiosarcoma remains poorly studied but using a doxorubicin-based chemotherapy regimen, a survival benefit can be achieved.
This is a preview of subscription content, log in via an institution to check access.
Literatur
Abendroth A, Bauer S (2013) Adjuvant chemotherapy for soft tissue sarcoma? A clear no – well – yes-ish. Dtsch Med Wochenschr 138(41):2107–2110
Chaabouni A, Rebai N, Chabchoub K et al (2013) Primary renal angiosarcoma: case report and literature review. Can Urol Assoc J 7(5–6):430–432
Kasper B, Sleijfer S, Litière S et al (2014) Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072. Ann Oncol 25(3):719–724
Leggio L, Addolorato G, Abenavoli L et al (2006) Primary renalangiosarcoma: a rare malignancy. a case report and review of the literature. Urol Oncol 24(4):307–312
Mark RJ, Poen JC, Tran LM et al (1996) Angiosarcoma. a report of 67 patients and review of the literature. Cancer 77(11):2400–2406
Penel N, Blay JY, Mir O et al (2014) ANGIOTAX-PLUS trial: a randomized phase II trial assessing the activity of weekly paclitaxel (WP) plus or minus bevacizumab (B) in advanced angiosarcoma (AS). J Clin Oncol 32:5s (suppl; abstr 10501)
Popper H, Thomas LB, Telles NC et al (1978) Development of hepatic angiosarcoma in man induced by vinyl chloride, thorotrast, and arsenic. Comparison with cases of unknown etiology. Am J Pathol 92(2):349–376
Russo P (2011) Adult Genitourinary Soft Tissue Sarcoma. In: Scardino P (Hrsg) Comprehensive Textbook of Genitourinary Oncology. Wolters Kluwer, S 870–880
Graaf WT van der, Blay JY, Chawla SP et al (2012) Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379(9829):1879–1886
Zenico T, Saccomanni M, Salomone U, Bercovich E (2010) Primary renal angiosarcoma: case report and review of world literature. Tumori 97(4):6–9
Einhaltung ethischer Richtlinien
Interessenkonflikt. J. Rüb, S. Bauer, J. Pastor, J. Noldus und R.J. Palisaar geben an, dass kein Interessenkonflikt besteht.
Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rüb, J., Bauer, S., Pastor, J. et al. Primär renales Angiosarkom. Urologe 54, 849–853 (2015). https://doi.org/10.1007/s00120-015-3809-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00120-015-3809-0